Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track GDTC with free AI briefings, catalyst countdowns, and dilution alerts.

GDTC · CytoMed Therapeutics Ltd

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.5M Cash on Hand
4.7mo Cash Runway
Follow GDTC by email Get an email when GDTC reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about GDTC, unsubscribe in one click. Privacy

📣 What GDTC Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Human Umbilical Cord derived MSCs Lupus Nephritis Phase 2 · NCT01539902 Unknown
Adoptive Cell Transfer of NKG2DL-targetting… Colorectal Cancer Phase 1 · NCT04107142 Unknown
Allogeneic NKG2DL-targeting Chimeric Antigen… Cancer Phase 1 · NCT05302037 Recruiting
human Mesenchymal Stem Cell (MSC) infusion… Aging Well Phase 1 · NCT04174898 Unknown

Also used in these trials (approved or third-party drugs, not GDTC's own candidates): Cyclophosphamide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

GDTC holds $1.5M in cash and short-term investments and burns about $936,010/quarter from operations, an estimated runway of 4.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 65 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GDTC files for a raise →

👥 Who Owns GDTC

Insiders 25.9% Other 5%+ holders 10.1% Institutions (5 holders) 0.8% Public and other holders 63.2%
HolderTypeShares% of sharesAs of
Chee Kong Choo
Director, 10% owner
Insider 3,003,996 25.40% 2026-10-12
mDR LTD 5%+ holder (13G) 1,191,523 10.07% 2026-10-12
Yoong Ying Tan
Chief Corporate Officer
Insider 25,781 0.22% 2026-03-18
Yvonne Goh
Chief Financial Officer
Insider 25,781 0.22% 2026-03-18
Keng Kiat Toh
Director
Insider 4,000 0.03% 2026-03-18
Chak Hua Yew
Director
Insider 2,469 0.02% 2026-03-18

Share count 11,828,435 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full GDTC picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GDTC and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.